Clinical Trial Results:
Effectiveness of Dapagliflozin + Saxagliptin to revert from a standard basalbolus
insulin treatment (BBIT) regimen to a basal supported oral therapy
(BOT) in patients with Type 2 Diabetes – a randomised double-blinded
study – a randomised double-blinded study
Summary
|
|
EudraCT number |
2015-005740-34 |
Trial protocol |
DE |
Global completion date |
|
Paediatric regulatory details
|
|
Is the trial part of an agreed EMA paediatric investigation plan? |
|
Is the trial in scope of article 45 of Regulation (EC) No 1901/2006? |
|
Is the trial in scope of article 46 of Regulation (EC) No 1901/2006? |
|
Results information
|
|
Results version number |
v1(current) |
This version publication date |
25 Sep 2021
|
First version publication date |
25 Sep 2021
|
Other versions |
|
Summary report(s) |
Dapa-Saxa_Prematurely ended trial |
Note: The legislation allows summary attachments to be posted instead of the full dataset for this trial. Refer to Commission Guideline 2012/C 302/03
for further information.